Drug Testing and Traffic Safety: What You Need to Know
archive: archived pipeline: cataloged verified
Get this paper ↗ (full text — opens at the source; we link to it, we don't host it)
Summary
This report, published by the National Highway Traffic Safety Administration (NHTSA), addresses the complexities and limitations of drug testing data used to assess traffic safety in the United States. As public and legislative attention on drugged driving has increased, so has the reliance on data from the Fatality Analysis Reporting System (FARS), a national census of fatal motor vehicle crashes. The authors aim to clarify the processes involved in obtaining and reporting drug use data to prevent misinterpretation of prevalence statistics. The report highlights that unlike alcohol data, which has been reliably used for decades to inform policy, drug data are fraught with inconsistencies that hinder accurate national or comparative analysis. The document examines the workflow of drug data collection, from forensic testing protocols to entry into FARS. It identifies significant methodological flaws, primarily the lack of standardized testing procedures across states and laboratories. Drug testing requires biological samples and costly toxicological analysis, leading to substantial missing data; in 2019, only 36.2% of fatally injured drivers had reported drug tests in FARS. Furthermore, the data are "missing not at random," meaning statistical imputation techniques used for alcohol data cannot be applied. Testing protocols vary widely by jurisdiction, influenced by local laws, resources, and laboratory capabilities. Some states test for hundreds of substances, while others test for few or none. Additionally, the report distinguishes between screening tests, which may yield false positives, and confirmatory tests, which provide quantitative results, noting that FARS does not currently differentiate between the two. The findings reveal that positive drug test results do not necessarily indicate impairment at the time of a crash. Many detected substances are prescription medications taken at therapeutic doses, or drugs administered during emergency medical treatment. Moreover, detection windows vary significantly by substance; for example, cannabis metabolites can remain in the body for weeks, whereas inhalants may be eliminated before sample collection. The report demonstrates that apparent increases in drug-involved fatalities often reflect changes in testing protocols, such as the addition of fentanyl to a testing panel, rather than actual increases in drug use. Consequently, comparisons of drug prevalence across states or years are often invalid due to these differential testing practices. The significance of this report lies in its caution against using current FARS drug data for definitive policy decisions or countermeasure planning without acknowledging these substantial limitations. The authors conclude that the current data cannot reliably estimate national drug-driving prevalence or support cross-jurisdictional comparisons. The report outlines NHTSA’s ongoing efforts to improve the quantity and quality of drug data in FARS, emphasizing the need for standardized testing and reporting to ensure that future data can accurately inform traffic safety initiatives.
Key finding
The report identifies that inconsistent drug testing protocols, high rates of missing data, and the inability to use statistical imputation due to non-random missingness severely limit the validity and comparability of drug prevalence estimates in the FARS database.
Methodology
review
Provenance
The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed. Discovered via bulk_ingest_rosap on 2026-05-23 (6 acquisition events logged).
| Stage | Outcome | Tool | Model | Prompt | Attempts | Completed |
|---|---|---|---|---|---|---|
| discover | success | rosap | — | — | 2 | 2026-05-23 |
| archive | success | — | — | — | 1 | 2026-05-23 |
| extract | success | cached | — | — | 2 | 2026-06-10 |
| clean | success | — | — | — | 1 | 2026-06-01 |
| chunk | success | — | — | — | 1 | 2026-06-01 |
| embed | success | — | — | — | 1 | 2026-06-02 |
| enrich | success | — | — | — | 1 | 2026-05-23 |
| promote | success | — | — | — | 1 | 2026-05-23 |
| summarize | success | llm | qwen3.6-27b-prismaquant | summ-v5 | 3 | 2026-06-10 |
| tag | success | vector_similarity | — | — | 19 | 2026-06-11 |
| verify | success | — | — | — | 2 | 2026-06-10 |
Summary generated by qwen3.6-27b-prismaquant on 2026-06-10; verification: verified.
Topics
Ranked by relevance to this paper. Hover a topic for its definition.
Information type
What kind of knowledge this paper contributes, grouped by family — independent of topic (what it is about) and method (how it was studied).
- Empirical Findings: crash risk outcomes
- Methodological Resource: dataset resource